Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Baxter International ( (BAX) ) has issued an update.
On July 7, 2025, Baxter International announced the appointment of Andrew Hider as the new President and CEO, effective by September 3, 2025. Brent Shafer will transition from Interim CEO to Non-Executive Chair of the Board. Hider, with extensive experience in automation solutions and a proven track record of growth and operational excellence, is expected to lead Baxter into its next chapter, focusing on innovation and sustainable growth.
The most recent analyst rating on (BAX) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
Baxter International’s overall stock score reflects a balanced view of mixed financial performance, stable technical indicators, and strong earnings call results. The most significant factors are its ability to maintain positive cash flow and strong earnings call performance, offset by valuation concerns due to negative P/E ratio and operational challenges highlighted in financial statements.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International Inc. is a global leader in medical technology, providing essential solutions in hospitals, physician offices, and other care sites. The company offers a wide range of connected solutions, medical devices, and advanced injectable technologies, with a mission to save and sustain lives.
Average Trading Volume: 4,025,395
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.91B
For an in-depth examination of BAX stock, go to TipRanks’ Overview page.